Tasnim News Agency |
Depression Raises Risk of Heart Failure by 40 Percent
Tasnim News Agency “We found a dose response relationship between depressive symptoms and the risk of developing heart failure. That means that the more depressed you feel, the more you are at risk,” Lise Tuset Gustad, first author of the study and an intensive care … |
Talywain mum fighting 'one-in-a-million' condition appeals for op – Free Press Series
Free Press Series |
Talywain mum fighting ‘one-in-a-million’ condition appeals for op
Free Press Series Her only hope, they feel, is to undergo an expensive stem cell transplant. Mrs Clarke added: “I absolutely, point blank, refuse for SPS to rob me of my life. I am not ready to die, it’s not my time. I have three beautiful, precious children I am … |
Billingham PCSO Lindsey Blackburn organises six events to help beat blood … – Gazette Live
Gazette Live |
Billingham PCSO Lindsey Blackburn organises six events to help beat blood …
Gazette Live But a stem cell transplant from her brother Stephen in April 2011 did the trick and three years on, she’s still in remission. Linda, 28, who has been a PCSO for more than six years and currently patrols in Billingham, said: “You have difficult days … |
Doctor sues Queensland Government for almost $2 million over baby delivery – Courier Mail
Doctor sues Queensland Government for almost $2 million over baby deliveryCourier MailDr Ismail, who later had two shoulder operations, had to have hydrocortisone injections and physiotherapy and will need further surgery. According to the claim, Dr Is…
Bollywood dreams – The Hindu
The Hindu |
Bollywood dreams
The Hindu David plays Robert, an artist diagnosed with liver cancer who falls in love with Maya, played by Shahana Goswami. David talks about the movie and his experience. Excerpts from … This is my first visit to India. I’ve a friend who has seen all parts of … |
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock … – Wall Street Journal
|
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock …
Wall Street Journal We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, … |
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR … – GlobeNewswire (press release)
|
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR …
GlobeNewswire (press release) SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, … Celladon Gets FDA’s “Breakthrough Therapy” Status for Gene TherapyXconomy Celladon Gets Breakthrough Therapy Designation For Mydicar From FDARTT News |
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock … – MarketWatch
|
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock …
MarketWatch We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, … |
Drug does not improve set of cardiovascular outcomes for diastolic heart failure – National Institutes of Health (press release)
2 Minute MedicineDrug does not improve set of cardiovascular outcomes for diastolic heart failureNational Institutes of Health (press release)A drug that blocks the action of a key hormone did not significantly improve a set of cardiovascular outcomes …
BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML … – News-Medical.net
|
BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML …
News-Medical.net Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx’s BL-8040 as a treatment for chronic myeloid leukemia (CML) in a … |